Rigshospitalet, Denmark — Biomedical Watch V2

Traitements10programmes

Essais6liés

Publications8liées

SourceDBlocale

Traitements

10

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
3 Year Follow up on ANO5 PatientsThe aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures	Myopathies	À vérifier	Ralentissement de la progression	Denmark	À vérifier
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 VariantsA large cohort of MRI scans from patients with pathogenic variants in the anoctamin 5 gene will be collected through an international collaboration to better describe muscle involvement.	Myopathies	À vérifier	À vérifier	Denmark	À vérifier
FexofenadineThe DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.	SEP	Phase 3	À vérifier	Denmark	À vérifier
MethylprednisoloneThis is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.	Cancer, Lupus, Myopathies, SEP	Phase 3	À vérifier	Denmark	À vérifier
ParacetamolThe DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.	SEP	Phase 3	À vérifier	Denmark	À vérifier
Physical Activity and Fatigue in Myasthenia GravisDanish patients with myasthenia gravis are asked to answer a validated and international questionnaire about physical activity. Also background questions about their disease and comorbidity are asked. To validate the data about physical activity from the questionnaires 69 patients are asked to wear an accelerometer for 7 days to measure activity level.	Myasthénie	À vérifier	Traitement symptomatique	Denmark	À vérifier
Physical Activity and Fatigue in Myasthenia GravisDanish patients with myasthenia gravis are asked to answer a validated and international questionnaire about physical activity. Also background questions about their disease and comorbidity are asked. To validate the data about physical activity from the questionnaires 69 patients are asked to wear an accelerometer for 7 days to measure activity level.	Myasthénie	À vérifier	Traitement symptomatique	Denmark	À vérifier
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 VariantsA large cohort of MRI scans from patients with pathogenic variants in the anoctamin 5 gene will be collected through an international collaboration to better describe muscle involvement.	Myopathies	À vérifier	À vérifier	Denmark	À vérifier
3 Year Follow up on ANO5 PatientsThe aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures	Myopathies	À vérifier	Ralentissement de la progression	Denmark	À vérifier
MethylprednisoloneThis is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.	SEP	Phase 2	Immunomodulation	United States	À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
Rituximab	SEP	Phase 3	NCT04688788	DanNORMS — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	ACTIVE_NOT_RECRUITING
Methylprednisolone	SEP	Phase 2	NCT02784210	Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	RECRUITING
3 Year Follow up on ANO5 Patients	Myopathies	À vérifier	NCT05206617	3 Year Follow up on ANO5 Patients	ACTIVE_NOT_RECRUITING
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	Myopathies	À vérifier	NCT05102799	ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	ACTIVE_NOT_RECRUITING
Physical Activity and Fatigue in Myasthenia Gravis	Myasthénie	À vérifier	NCT03905473	Physical Activity and Fatigue in Myasthenia Gravis	COMPLETED
Sildenafil	Myopathies	Phase 2	NCT01350154	Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	COMPLETED

Publications

8

Molécule	Indication / population	Titre	Journal	Date
Methylprednisolone		Wt1 facilitates visceral beige fat formation to combat abdominal obesity.	Adipocyte
Methylprednisolone		Kidney transplantation in sub-Sahara African countries: challenges and lessons from the experience of Cameroon: a preliminary report of the first 17 pioneer cases.	Renal failure
3 Year Follow up on ANO5 Patients		Clinical and genetic features of anoctaminopathy in Saudi Arabia.	Neurosciences (Riyadh, Saudi Arabia)
3 Year Follow up on ANO5 Patients		A hospital based epidemiological study of genetically determined muscle disease in south western Norway.	Neuromuscular disorders : NMD
Methylprednisolone		Recent advances in the medical management of thyroid eye disease.	Current opinion in endocrinology, diabetes, and obesity
Methylprednisolone		AQP4-IgG-positive myelitis occurring in a patient with small cell lung cancer: a case report.	Frontiers in oncology
Methylprednisolone		Paroxysmal Speech Arrest With Resolving Splenial and Symmetric White Matter Lesions in a Child: A Case Report.	Cureus
Methylprednisolone		Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.	Neurology